July 2025 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)
Crystal Research Associates has issued a 16-page Company Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Snapshot of GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing next-generation vaccines and immunotherapies for serious infectious diseases and solid tumors. Its lead infectious disease candidate, GEO-CM04S1, is a multi-antigen COVID-19 vaccine designed to provide broader, longer-lasting protection, especially for immunocompromised individuals. Currently in three Phase 2 trials, GEO-CM04S1 is being studied in healthy adults, patients with Chronic Lymphocytic Leukemia (CLL), and individuals undergoing stem cell transplant or CAR-T therapy.
In oncology, GeoVax is preparing a new Phase 2 trial of Gedeptin® as a neoadjuvant therapy for head and neck squamous cell carcinoma, in combination with pembrolizumab and fludarabine. Additional preclinical studies are ongoing in other tumor types. T
he Company’s Mpox and smallpox vaccine candidate, GEO-MVA, is expected to enter clinical trials in late 2025, following favorable guidance from the European Medicines Agency supporting a streamlined development path. Backed by global rights, a growing intellectual property portfolio, and scalable manufacturing capabilities—including a transition to cell-based platforms—GeoVax is led by an experienced management team focused on advancing high-impact vaccines and immunotherapies to address urgent and underserved medical needs.
Key Points
- On July 28, 2025, GeoVax reported a net loss of $5.4 million ($0.35 per share) for Q2 2025, compared to a net loss of $5.1 million ($1.99 per share) in Q2 2024.
- Key pipeline programs advanced during the quarter, including favorable European Medicines Agency (EMA) guidance for GEO-MVA and strong immune response data from GEO-CM04S1 in immunocompromised patients, particularly those with Chronic Lymphocytic Leukemia (CLL).
- GEO-MVA is now positioned for centralized EU approval and global procurement access. As the only U.S.-based MVA vaccine developer for Mpox/smallpox, GeoVax is targeting a $10 billion+ market amid rising demand and transitioning to scalable, cell-based manufacturing.
- Preparations are underway for a Phase 2 trial of Gedeptin® in head and neck cancer, reinforcing GeoVax’s focus on immunotherapies for underserved oncology indications.
- During the quarter, Dr. Senthil Ranganathan joined as VP of Technical Development and CMC Operations, bringing 20+ years of biologics and manufacturing expertise across vaccines, viral vectors, and cell and gene therapies.
- GeoVax further strengthened its IP portfolio with a new U.S. patent covering its malaria vaccine platform and a Notice of Allowance for claims related to Gedeptin® combined with radiation therapy. The Company now holds over 135 patents across 23 families, supporting its multi-antigenic approach to infectious disease and cancer.
- GeoVax ended Q2 with $3.1 million in cash and completed a public offering in July 2025, raising $5.6 million in net proceeds to support operations and near-term growth.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.
*******************************************
See report for full disclosure and disclaimer details.
